Tag:
Pharma taxes
Latest Headlines
Latest Headlines
Report: Pharma cuts jobs after benefiting from repatriation break
Drugmakers helping to lobby for a "tax holiday" on repatriated foreign cash say the break would create jobs. But a new report finds companies that benefited from the 2004 repatriation-tax
AZ to pay $1.1B in better-than-expected tax deal
AstraZeneca ( $AZN ) has put a long-running tax dispute to rest. And paradoxically, the company's tax bill will actually boost its earnings this year. The drugmaker reached a deal with UK and U.S.
Emerging markets crack down on transfer pricing
Pharma's tax strategies have captured a lot of attention lately. First, the U.S. government made noises about changing tax rules for overseas profits. Then AstraZeneca settled a transfer-pricing
Tax strategies of the profitable and savvy
No one can accuse Big Pharma of taxpayer naiveté. Many drugmakers use elaborate strategies to make sure as much of their profits as possible reside in tax-friendly locales. The ensuing
EMA chief tells pharma to expect higher fees
The European financial crisis could put the squeeze on drug prices in the E.U. Indeed, debt-laden Greece and fiscally wobbly Spain have both announced plans to cut their drug spending. But the
Pharma's 'aggressive' tax-avoidance tactics draw fire
Big Pharma is catching fire for "aggressive tax planning." Apparently, some big drugmakers are taking advantage of legal loopholes in the tax code, by booking losses in high-tax jurisdictions--such
AZ settles U.K. tax dispute for $783M
AstraZeneca has settled a longstanding tax dispute with U.K. authorities, promising to pay 505 million pounds, or $783 million. The main issue: Transfer pricing that affected more than 15 years of
Pharma to pay under Obama tax plan
How does pharma fare under President Obama's proposed budget? The short answer is so-so. Generics makers would have to pay new fees. Multinational pharma firms most likely would pay more in taxes.
Allergan says 'Botax' wouldn't hurt sales much
Botox maker Allergan says a proposed tax on cosmetic surgeries and procedures-- such as Botox injection --would have a small impact on the company, but it's still actively fighting the measure. Report
Danger, Big Pharma: Higher taxes ahead
Drugmakers, the taxman cometh. As if pharma didn't have enough bogeymen to worry about, right? PricewaterhouseCoopers is warning that as companies do the things they need to do to combat stagnant
